tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ACLX Stock Latest News

Arcellx resumed with a Buy at Stifel
The FlyArcellx resumed with a Buy at Stifel
9d ago
ACLX
Arcellx assumed with a Neutral at Cantor Fitzgerald
PremiumThe Fly
Arcellx assumed with a Neutral at Cantor Fitzgerald
16d ago
ACLX
Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Efficacy, Safety, and Financial Position
PremiumRatings
Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Efficacy, Safety, and Financial Position
19d ago
ACLX
Arcellx Inc’s Strong Positioning and Financial Stability Support Buy Rating Amid Anticipated FDA Approval
PremiumRatings
Arcellx Inc’s Strong Positioning and Financial Stability Support Buy Rating Amid Anticipated FDA Approval
1M ago
ACLX
3 Stocks to Buy Now, According to the Technical Analysis
PremiumMarket News
3 Stocks to Buy Now, According to the Technical Analysis
2M ago
CXW
ACLX
Promising Clinical Outcomes and Low Toxicity Profile Position Anito-cel as a Leading Therapy for Relapsed/Refractory Multiple Myeloma
PremiumRatingsPromising Clinical Outcomes and Low Toxicity Profile Position Anito-cel as a Leading Therapy for Relapsed/Refractory Multiple Myeloma
2M ago
ACLX
Arcellx, Inc. Reports Increased Losses Amid Rising R&D Costs
Premium
Company Announcements
Arcellx, Inc. Reports Increased Losses Amid Rising R&D Costs
2M ago
ACLX
Promising Prospects for Arcellx Inc: Strong Efficacy and Strategic Partnerships Drive Buy Rating
Premium
Ratings
Promising Prospects for Arcellx Inc: Strong Efficacy and Strategic Partnerships Drive Buy Rating
3M ago
ACLX
Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Anito-cel Therapy Performance and Favorable Safety Profile
PremiumRatings
Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Anito-cel Therapy Performance and Favorable Safety Profile
3M ago
ACLX
Arcellx Inc: Promising Developments and Strong Clinical Data Drive Buy Rating
PremiumRatings
Arcellx Inc: Promising Developments and Strong Clinical Data Drive Buy Rating
3M ago
ACLX
Arcellx reports Q2 EPS (94c), consensus ($1.03)
PremiumThe Fly
Arcellx reports Q2 EPS (94c), consensus ($1.03)
3M ago
ACLX
These 3 Stocks Are Screaming ‘Strong Buy,’ According to the Technical Analysis
PremiumMarket News
These 3 Stocks Are Screaming ‘Strong Buy,’ According to the Technical Analysis
3M ago
ACLX
JAZZ
Arcellx’s Innovative CAR-T Therapy Study for GMG: A Potential Game-Changer
PremiumCompany AnnouncementsArcellx’s Innovative CAR-T Therapy Study for GMG: A Potential Game-Changer
3M ago
ACLX
Arcellx price target raised to $133 from $93 at Scotiabank
Premium
The Fly
Arcellx price target raised to $133 from $93 at Scotiabank
3M ago
ACLX
Arcellx Advances Phase 3 Study for Multiple Myeloma Treatment
Premium
Company Announcements
Arcellx Advances Phase 3 Study for Multiple Myeloma Treatment
3M ago
ACLX
Arcellx initiated with a Buy at Citi
PremiumThe Fly
Arcellx initiated with a Buy at Citi
4M ago
ACLX
Arcellx Inc’s Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment
PremiumRatings
Arcellx Inc’s Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment
4M ago
ACLX
Arcellx Inc’s Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position
PremiumRatings
Arcellx Inc’s Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position
4M ago
ACLX
Arcellx Inc’s Anito Cel Therapy: A Promising Contender in Multiple Myeloma Treatment with Strong Market Potential
PremiumRatings
Arcellx Inc’s Anito Cel Therapy: A Promising Contender in Multiple Myeloma Treatment with Strong Market Potential
4M ago
ACLX
Promising Potential of Arcellx Inc’s Anito-cel Therapy Drives Buy Rating
PremiumRatingsPromising Potential of Arcellx Inc’s Anito-cel Therapy Drives Buy Rating
4M ago
ACLX
Positive Outlook for Arcellx Inc: Promising Anito-cel Therapy and Strategic Market Positioning
Premium
Ratings
Positive Outlook for Arcellx Inc: Promising Anito-cel Therapy and Strategic Market Positioning
4M ago
ACLX
Arcellx Inc’s Promising Market Position and Growth Potential in Multiple Myeloma Therapy
Premium
Ratings
Arcellx Inc’s Promising Market Position and Growth Potential in Multiple Myeloma Therapy
4M ago
ACLX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >